Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Sean Pittock, MD, director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval. 

Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment

ION541, an antisense oligonucleotide, failed to demonstrate impact on outcomes of function, breathing, and strength, in addition to no impact on neurofilament light.

Biogen, Ionis Terminate BIIB105 Following Disappointing Phase 1/2 Results

Videos

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Dosing Commenced in Study of Anti-Tau Agent, FDA Updates Labeling to Glatiramer Acetate Products, Eisai Initiates Rolling Submission for Subcutaneous Lecanemab 

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024. 

NeurologyLive® Friday 5 — May 17, 2024

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD

, has been with the team since October 2019. Follow him on Twitter 

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

CMSC 2024: What to Expect From This Year's Annual Meeting

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Siegel Rare Neuroimmune Association

Mayo Clinic

SAP Partners

Episode 1: Clinical Presentation of Neuroimmune Disorders

Episode 2: Accurately Ensuring Diagnosis With Thorough Clinical Evaluation and History

Episode 3: Attention to Detail With Biomarkers in Rare Neuroimmune Disorders

Episode 4: Understanding the Need for Additional Help, Emergency Care With Neuroimmune Disorders

Episode 5: Avoiding and Troubleshooting Misdiagnosis of Rare Neuroimmune Disorders

The Siegel Rare Neuroimmune Association (SRNA) is a not-for-profit organization dedicated to the support of children, adolescents, and adults with a spectrum of rare neuroimmune disorders including: Acute Disseminated Encephalomyelitis (ADEM), Acute Flaccid Myelitis (AFM), MOG Antibody Disease (MOGAD), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM). We support individuals living with rare neuroimmune diagnoses and their families, promote awareness to empower patients, families, clinicians and scientists, build a collaborative and dedicated clinical care network and help advance scientific understanding and research.

Acute Flaccid Myelitis (AFM) Physician and Consult Support Portal

Acute Flaccid Myelitis (AFM) Resources for Families and Clinicians

Disorder Information Sheets/Resources - Spanish

SAP Partner

Experts such as Brenda Banwell, MD; Sean Pittock, MD; and Michael Levy, MD, PhD, cover topics related to differences in rare neuroimmune disorders, how they're approached and treated.

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

SRNA Roundtable Discussion: Diagnosis, Presentation, and Treatment Decision Differences Among Rare Neuroimmune Disorders